Larimar Therapeutics, Inc.

LRMR

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

RTW Investments Deerfield Management Driehaus Capital

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management0.0%Feb 17, 2026

SC 13GRA Capital Management9.5%Feb 26, 2024

SC 13G/A

Position Details

RTW InvestmentsNEWFeb 17, 2026

Shares: 3,125,000Value: $11.9M

**Signal Note: RTW Investments enters LRMR** RTW Investments' $11.9M initiation in Larimar suggests conviction in seribantumab (MM-121), a HER3/EGFR inhibitor in development for NRG1 fusion-positive cancers—a genetically-defined subset with limited treatment options and potential for rapid clinical validation. The timing likely reflects upcoming clinical readouts or partnership catalysts, though LRMR remains a pre-revenue clinical-stage play with execution risk tied to patient enrollment and efficacy durability in this orphan indication.

Deerfield ManagementNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

NBIX3 funds PODD3 funds BBNX3 funds SYRE3 funds ARWR3 funds CELC3 funds CMPS3 funds TNDM

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

# Signal Note: Deerfield Initiates $116.6M Position in Larimar Therapeutics Deerfield's substantial new stake in LRMR signals conviction in seribantumab, a fibroblast growth factor receptor (FGFR) inhibitor in development for achondroplasia, the most common form of dwarfism. The timing aligns with anticipated regulatory catalysts: LRMR completed a Phase 3 study in achondroplasia and is advancing toward potential FDA submissions, representing a rare orphan indication with clear clinical endpoints. This represents a meaningful validation from a tier-1 healthcare investor ahead of what could be transformational newsflow for the company.